TARDBP and Alzheimer disease: It is expected that individuals who have a worse clinical than biological AD stage would show signs of other brain pathologies, such as Lewy body pathology, cerebral small vessel disease, or limbic-predominant age-related TAR DNA-binding protein 43 (TDP-43) encephalopathy disease, whereas those who perform clinically better than expected based on their biomarkers might have greater resilience to AD pathology.4,5 However, it has not yet been tested in the context of the new staging criteria, which was the goal of the current study.